

**DRAFT PROGRAM (as of 5/8/26) Timing, Presentation Titles, and Speakers Subject to Change.**



## IPAC-RS Nasal Innovation Forum

Wednesday - Thursday, September 16- 17, 2026 *(In-Person Event)*

[Liberty House](#) - 76 Audrey Zapp Drive, Jersey City, NJ 07305  
(See [website](#) for logistical details)

Day 1 – Wednesday, September 16, 2026	
8:00 – 8:15 AM	Check In and Continental Breakfast
8:15 – 8:25 AM	Housekeeping and Rules of Engagement <a href="#">Mary Devlin Capizzi, Faegre Drinker, IPAC-RS Secretariat</a>  Welcome and Introduction <a href="#">Carolyn Berg, Catalent Pharma Solutions</a>
8:25 – 9:00 AM	Patient Perspective Keynote Introduction <a href="#">Robin Boyd, Neurelis</a>  Patient Ambassador <a href="#">Danielle Lance Purpich</a>
Session 1: Roadmap: From Discovery into the Clinic <a href="#">Moderator: Reenal Gandhi, Aptar Pharma</a>	
9:00 – 9:20 AM	Engineering the Nasal Portal of Defense: A Mucoadhesive Platform for Ambient-Stable Protein Prophylactics Against Influenza <a href="#">Ashlee Brunaugh, University of Michigan</a>
9:20 – 9:45 AM	Key Considerations from Innovation to Clinic: Translating Nasal Formulation Development Strategy from Pre IND to CTM <a href="#">Paul Shields, Aptar Pharma</a>
9:45 – 10:05 AM	Progress Towards A Nasal Klebsiella Pneumoniae Vaccine <a href="#">Elizabeth Norton, Tulane University</a>
10:05 – 10:30 AM	Insights into Molecule Repurposing <a href="#">Michael Lusty, Consultant</a>
10:30 – 11:00 AM	Coffee Break & Networking
Session 2: Device Selection <a href="#">Moderator: Carolyn Berg, Catalent Pharma Solutions</a>	
11:00 – 11:25 AM	Insights into Intranasal Oligonucleotide Delivery: From Formulation and Process Design to Device Performance <a href="#">Sana Hosseini, Aptar Pharma</a> and <a href="#">Silvia Matiz, Nanopharm</a>
11:25 – 11:50 AM	From Concept to Clinic: Developing a Patient-Centric and Versatile Intranasal Dry Powder Platform <a href="#">Alain Regard, Nemera</a> and <a href="#">Louise Rawcliffe, Therakind</a>
11:50 AM – 12:15 PM	Supporting Device Selection: Anatomical Models in Intranasal Drug Delivery <a href="#">Laleh Golshahi, Virginia Commonwealth University</a>

**DRAFT PROGRAM (as of 5/8/26) Timing, Presentation Titles, and Speakers Subject to Change.**

<b>12:15 – 1:30 PM</b>	<b>Lunch Break &amp; Networking</b>
<b>Session 3: Manufacturing Best Practices</b> <b>Moderator: Irene Rossi, Harro Höfliger</b>	
<b>1:30 – 1:55 PM</b>	<b>Manufacturing Nasal Powders: Key Spray Drying Process Considerations</b> <b>Molly Adam, Lonza</b>
<b>1:55 - 2:20 PM</b>	<b>From Concept to Commercialization: Strategic Decision Making for Prototyping, CMC, Device Development, and Clinical in Nasal Spray Products</b> <b>Kiran Chaudhari, Hikma</b>
<b>2:20 – 2:45 PM</b>	<b>Filling and Assembly of Nasal Rescue Products</b> <b>Jonas Sävmarker, Orexo AB</b>
<b>Rapid Fire Device Showcase and Panel Discussion (7-minute presentations, followed by Q&amp;A)</b> <b>Moderator: Maria Smith, Proveris Scientific Corporation</b>	
<b>2:45 – 3:30 PM</b>	<ul style="list-style-type: none"> <li>• Nemera</li> <li>• Resyca</li> <li>• Iconovo</li> <li>• Two Others Invited (to be announced)</li> </ul> <p>Q&amp;A (10 min)</p>
<b>3:30 – 4:00 PM</b>	<b>Coffee Break &amp; Networking</b>
<b>Investor Roundtable: Inside the VC Mindset</b> <b>Moderator: Ryan Kole, beyond Barriers</b>	
<b>4:00 – 5:00 PM</b>	Venture Capital Companies Invited (TBA) Q&A
<b>5:00 – 6:30 PM</b>	<b>Happy Hour &amp; Networking</b>

<b>Day 2 – Thursday, September 17, 2026</b>	
<b>8:00 – 8:20 AM</b>	<b>Check In and Continental Breakfast</b>
<b>8:20 – 8:30 AM</b>	<b>Welcome and Introduction to Day 2</b> <b>Mark Parry, Intertek</b>
<b>8:30 – 9:00 AM</b>	<b>Keynote TBA</b>
<b>Session 4: Successful Case Studies</b> <b>Moderator: Mark Parry, Intertek</b>	
<b>9:00 – 9:20 AM</b>	<b>Enhancing Local Innate Immunity to Prevent Respiratory Viral Infection: Clinical Translation of a Nasal Immunomodulator</b> <b>Christophe Demaison, ENA Respiratory Pty Ltd</b>
<b>9:20– 9:40 AM</b>	<b>Engineering D-MAVs, Designable Multi-Antivirals, for Nasal Administration</b> <b>Michael Lipp, Decoy Therapeutics Inc.</b>
<b>9:40 – 10:00 AM</b>	<b>Title (TBA)</b> Speaker TBC

**DRAFT PROGRAM (as of 5/8/26) Timing, Presentation Titles, and Speakers Subject to Change.**

10:00 – 10:20 AM	Title (TBA) Speaker TBC
10:20 – 10:45 AM	Coffee Break & Networking
Session 5: Regulatory Pathway Moderator: TBC	
10:45 – 11:05 AM	Bridging the Gap: Turning Nasal Development Data into Regulatory Success <a href="#">Maria Smith, Proveris Scientific Corporation</a>
11:05 – 11:25 AM	Regulatory Perspective FDA Invited; Speaker TBC
11:25 – 11:45 AM	Regulatory Perspective MHRA Invited; Speaker TBC
11:45 AM – 12:05 PM	Regulatory Perspective EMA Invited; Speaker TBC
12:05 – 12:30 PM	Panel
12:30 PM	Closing Remarks